Rhythm Pharmaceuticals has launched Imcivree (setmelanotide) in Germany to treat obesity and control of hunger associated with Bardet-Biedl syndrome (BBS).

A melanocortin-4 receptor (MC4R) agonist, Imcivree has been designed for the treatment of hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases.

The German Federal Joint Committee (G-BA) has approved the eligibility of Imcivree for federal reimbursement by statutory health insurance for BBS in the country.

Rhythm Pharmaceuticals executive vice-president and international head Yann Mazabraud stated: “We are excited and well-prepared to bring Imcivree to patients in Germany, which is an important market with many identified patients in need of a therapy for hyperphagia and severe obesity that significantly burden people living with BBS and their families.

“Receiving exemption status from the G-BA to provide access to Imcivree is an important recognition of the severity of BBS and further reinforces the critical distinction between rare MC4R pathway diseases and general obesity.”

The US Food and Drug Administration (FDA) approved Imcivree to offer chronic weight management in adult and paediatric patients aged six years and above living with monogenic or syndromic obesity caused by deficiency of pro-opiomelanocortin (POMC), leptin receptor (LEPR) or proprotein convertase subtilisin/kexin type 1 (PCSK1).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The drug has also been authorised by the European Commission and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to treat obesity and control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency.